Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
NOVO Nordisk's board is working to find a replacement for chief executive officer Lars Rebien Soerensen, who led the Danish company to one of the best stock market performances of any drugmaker over the past 14 years.
Mr Rebien Soerensen, 60, is unlikely to remain in the...